David S. Marks
Corporate Officer/Principal presso The Medical College of Wisconsin, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Shekar Kurpad | M | - |
The Medical College of Wisconsin, Inc.
| 10 anni |
John R. Raymond | M | - |
The Medical College of Wisconsin, Inc.
| - |
Dennis J. Kuester | M | 82 |
The Medical College of Wisconsin, Inc.
| - |
Michael E. Mitchell | M | - |
The Medical College of Wisconsin, Inc.
| - |
Samantha Adler | F | - |
The Medical College of Wisconsin, Inc.
| - |
Julie Idzikowski | F | - |
The Medical College of Wisconsin, Inc.
| - |
Seth Flynn | M | - |
The Medical College of Wisconsin, Inc.
| - |
Elsa Knysak-Wolfe | F | - |
The Medical College of Wisconsin, Inc.
| - |
Meg Bilicki | F | - |
The Medical College of Wisconsin, Inc.
| - |
Allen Cowley | M | - |
The Medical College of Wisconsin, Inc.
| - |
Christopher Miskel | M | 49 |
The Medical College of Wisconsin, Inc.
| - |
Peggy Troy | F | 72 |
The Medical College of Wisconsin, Inc.
| - |
Ehab L Atallah | M | - |
The Medical College of Wisconsin, Inc.
| 17 anni |
Parameswaran Hari | M | - |
The Medical College of Wisconsin, Inc.
| - |
Jay Williams | M | 72 |
The Medical College of Wisconsin, Inc.
| - |
George J. Korkos | M | 92 |
The Medical College of Wisconsin, Inc.
| - |
Mary Stanek | F | 67 |
The Medical College of Wisconsin, Inc.
| - |
Brian H. Kopell | M | 53 |
The Medical College of Wisconsin, Inc.
| 20 anni |
Mary Anne Papp | F | - |
The Medical College of Wisconsin, Inc.
| - |
Fred Robertson | M | 68 |
The Medical College of Wisconsin, Inc.
| 31 anni |
John W. Daniels | M | 75 |
The Medical College of Wisconsin, Inc.
| - |
Phil Flynn | M | 66 |
The Medical College of Wisconsin, Inc.
| - |
Walter G. Winding | M | - |
The Medical College of Wisconsin, Inc.
| - |
G. Frederick Kasten | M | 85 |
The Medical College of Wisconsin, Inc.
| - |
John Shiely | M | 71 |
The Medical College of Wisconsin, Inc.
| - |
Timothy Hoeksema | M | 77 |
The Medical College of Wisconsin, Inc.
| - |
John Donofrio | M | 62 |
The Medical College of Wisconsin, Inc.
| - |
Cory Nettles | M | 54 |
The Medical College of Wisconsin, Inc.
| - |
Owen Sullivan | M | 66 |
The Medical College of Wisconsin, Inc.
| - |
Elizabeth Brenner | F | 69 |
The Medical College of Wisconsin, Inc.
| - |
Marie Nakata | F | - |
The Medical College of Wisconsin, Inc.
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Gregory Lambrecht | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | - |
William T. Hayes | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 anni |
Richard T. Spencer | M | 87 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 anni |
Jonathan M. Rourke | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 anni |
Katharine M. Stohlman | F | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 anni |
Christopher D. Hutchins | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 8 anni |
John Liddicoat | M | 60 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 13 anni |
William Cohn | M | 64 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 16 anni |
A. Marc Gillinov | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 13 anni |
Stanley B. Kyi | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 41 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- David S. Marks
- Contatti personali